ArticleAntimicrobial agents and chemotherapy2016

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.

Frederick C Lahser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.